Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe

NCT06919796 is registered in ClinicalTrials.gov with PharmaJet, Inc. as lead sponsor.

NCT NCT06919796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06919796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe
Lead sponsor
PharmaJet, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
November 25, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

evaluate immune responses following mrna covid-19 vaccine administration through different delivery routes in healthy volunteers, sars cov-2